CCL9/10/MIP-1 gamma Antibody [Alexa Fluor® 750]

• Applications: WB, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 750

CCL9/10/MIP-1 gamma Antibody [Alexa Fluor® 750] Summary

• Immunogen: E. coli-derived recombinant mouse CCL9/10/MIP‑1γ
  Gln22-Gln122
  Accession # Q3U9T8
• Specificity: Detects CCL9/10/MIP‑1 gamma in direct ELISAs and Western blots. In direct ELISAs, less than 25% cross-reactivity with recombinant mouse C10 is observed and less than 1% cross-reactivity with recombinant human MPIF-1 is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

Mouse CCL9/10 (also named MIP-1 gamma and MRP-2) is an 11 kDa, secreted, monomeric polypeptide that belongs to the beta (or CC) intercrine family of chemokines (1‑3). Based on its activity and amino acid (aa) sequence, it is further classified as a member of the NC6 or six cysteine-containing CC subfamily of chemokines (2, 4, 5). This subfamily contains four N-terminally extended chemokines, two human (CCL15 and CCL23) and two mouse (CCL9 and CCL10). Within this subfamily, there are no human-to-rodent interspecies orthologs. Mouse CCL9/10 is synthesized as a 122 aa precursor that contains a 21 aa signal sequence and a 101 aa mature region with six cysteines. As noted, the mature region has an expanded N-terminus relative to other CC family members, and it forms a third intrachain disulfide bond with its two extra cysteines (3‑7). Mouse CCL9/10 is 75% aa identical to rat CCL9/10 (8). Chemokines are known to undergo proteolytic processing to generate multiple isoforms. NC6 chemokines are usually only marginally active at full length, but are converted to highly active forms upon N-terminal truncation. Mature CCL9, in the presence of inflammatory fluids, is naturally truncated by 28, 29 or 30 aa at the N-terminus, generating a highly active, 8 kDa, 71‑73 aa CCR1 ligand. In contrast, other CCR1 ligands, CCL3/MIP-1 alpha and CCL5/RANTES, lose their potency when proteolytically processed. CCL9/10 is constitutively secreted, and circulates as a full‑length molecule. Any onset of inflammation with subsequent enzyme release may act on local NC6 chemokines, generating early, potent leukocyte chemoattractants (5, 7).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.